COVID-19 Blog - Microbix

Respiratory virus multiplex formulations desiccated on Copan’s FLOQSwab© for use as cross-platform compatible EQA samples – and laboratory Quality Control

Jun 20, 2023

https://microbix.com/wp-content/uploads/2022/05/ECCMID-2022-FINAL-March-29-2022.pdf

Jun 20, 2023

Innovative “EQA” Program to Qualify Labs for Genital Ulcer Disease Testing MISSISSAUGA, CANADA & HELSINKI, FINLAND – June 20, 2023 –...

Jun 18, 2023

https://microbix.com//wp-content/AACC 2023 Final 21JUL2023.pdf

Jun 18, 2023

https://microbix.com/wp-content/ASM 2023_FINAL COMMERCIAL COPY June 12 2023.pdf

Jun 13, 2023

FLOQSwab-formatted QAPs supporting PCR Tests for Antibiotic-Resistant Pathogens MISSISSAUGA, CANADA, June 13, 2023 – Microbix Biosystems...

May 23, 2023

In vitro diagnostics play a critical role in diagnosing and monitoring infectious diseases. Accurate and reliable test results are...

May 19, 2023

Applies for 12-month Term Extension of May 2021 Warrants MISSISSAUGA, CANADA, May 18, 2023 - Microbix Biosystems Inc. (TSX: MBX, OTCQB:...

May 16, 2023

Point of care (POC) testing has revolutionized the way we diagnose and manage various infectious diseases, including sexually transmitted...

May 16, 2023

Kinlytic® urokinase to be developed for re-entry into U.S. market MISSISSAUGA, CANADA, May 16, 2023 – Microbix Biosystems Inc. (TSX: MBX,...

May 11, 2023

Sales of $4.2 million and Profitability MISSISSAUGA, May 11, 2023 - Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life...